Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisagenlecleucel vs Standard of Care in Relapsed or Refractory Follicular Lymphoma
NCT05888493Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2023
- Primary completion
- Jul 2028
- Modality
- CAR-T Cells
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of tisagenlecleucel in follicular lymphoma (FL) (2 arms), sponsored by Novartis. Primary endpoint: Progression-free survival at 5 years. Started Oct 2023; status: active, not recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05888493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05888493.